Keros Therapeutics, Inc. (KROS)
| Market Cap | 223.99M |
| Revenue (ttm) | 244.06M |
| Net Income (ttm) | 87.01M |
| Shares Out | 19.72M |
| EPS (ttm) | 2.30 |
| PE Ratio | 4.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,063 |
| Open | 11.36 |
| Previous Close | 11.01 |
| Day's Range | 11.34 - 11.47 |
| 52-Week Range | 10.42 - 22.55 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 21.86 (+92.43%) |
| Earnings Date | May 6, 2026 |
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for KROS stock is "Buy." The 12-month stock price target is $21.86, which is an increase of 92.43% from the latest price.
News
Keros Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Significant progress included the transition of elritercept to Takeda, advancement of rinvatercept into DMD and ALS, and discontinuation of cibotercept. Rinvatercept showed promising Phase 1 results, and the ALS program was selected for a major consortium trial. Early pipeline expansion and a strong financial runway extend into 2028.
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Rinvatercept (KER-065) is advancing to phase II trials in DMD and ALS, showing strong preclinical and phase I data for muscle, bone, and fat improvements. The DMD trial will focus on late ambulatory and early non-ambulatory cohorts, with initial combination therapy alongside glucocorticoids. Significant Takeda partnership supports the pipeline.
Keros Therapeutics Appoints Charles Newton to its Board of Directors
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing rinvatercept for DMD and ALS, with a DMD trial starting this quarter and ALS regulatory engagement planned for the second half of the year. Elritercept, partnered with Takeda, is in phase III for MDS and MF, with commercialization targeted for late this decade. Cash reserves of $383M provide runway into 2028.
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Announces Final Results of Tender Offer
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) ...
Keros Therapeutics Announces Preliminary Results of Tender Offer
LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Of...
Keros Therapeutics Reports Third Quarter 2025 Financial Results
LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., ...
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel thera...
Keros Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Significant strategic changes include asset partnership, pipeline focus on KER-065, and a $375M capital return. KER-065 shows promise in DMD with improved safety and efficacy, while Takeda advances partnered programs. Regulatory and clinical milestones are upcoming.
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
AUSTIN, Texas , Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or th...
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therap...
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug....
Keros Therapeutics Reports Second Quarter 2025 Financial Results
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therap...
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas , June 9, 2025 /PRNewswire/ -- ADAR1...
Keros Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025
The company is refocusing on neuromuscular diseases, especially DMD, with KER-065 as its lead asset after out-licensing Aritrecept and discontinuing Subotrecept. $375M will be returned to shareholders, and cost-saving measures are in place to support ongoing research and development.
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Concludes Strategic Alternatives Review and Provides Update on Development of KER-065
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therap...
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeu...